– Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall 2025 – “These data presented for ABI-5366 and ABI-1179 continue to support ...
– Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall 2025 – SOUTH SAN FRANCISCO, Calif., July 26, 2025 (GLOBE NEWSWIRE) -- ...
Gilead Sciences GILD recently announced that it has exercised its combined option to exclusively license Assembly Biosciences’ ASMB herpes simplex virus (HSV) helicase-primase inhibitor programs. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results